Dr. John Talley headlines new medicinal chemistry provider

Inventor of CelebrexTM serves as chief scientific officer for St. Louis-based SARmont

ST. LOUIS (May 25, 2011) - The scientific mind behind pharmaceutical market- changers CelebrexTM and three HIV/AIDS treatments will lead the drug design team at the new St. Louis-based medicinal chemistry service provider, SARmont.Dr. John Talley, one of the world's most accomplished medicinal chemists, has helped eight drugs successfully reach the market. As chief scientific officer of SARmont, Talley will personally oversee all drug design and optimization projects for clients to identify high quality and proprietary investigational new drug (IND) lead candidates. Randy Weiss, a successful entrepreneur who has brought several life science companies to fruition, serves as SARmont's first president and CEO.

"SARmont partners with pharmaceutical companies, venture capital firms and research institutions to help bring promising new drugs to the market," said Talley. "By helping our clients overcome obstacles of pre-clinical pharmaceutical research, we increase the probability of success."

SARmont acts as the virtual arm of medicinal chemistry for its clients to provide superior drug design and lead optimization services. This approach helps streamline and accelerate the drug design process, giving clients access to the best minds in the business without having to build or hire an internal medicinal chemistry department.

Among the experts on SARmont's management team are President and CEO Dr. Randy Weiss, a former venture capitalist and serial entrepreneur; Director of Operations Dr. Eduardo Martinez, who started Microbia'schemistry group and managedMedrosas its inaugural employee; and Dr. Rick Ryan, former president of LINCO Research and VP of Drug Discovery and Development at Millipore, who will serve as SARmont's vice president of business development.

"SARmont is a trusted strategic partner that provides medicinal chemistry design and lead optimization services that put the focus on efficient and cost-effective success," added Ryan. "In an increasingly competitive market, our unique partnership approach ensures that SARmont clients own any intellectual property that's generated to help them institutionalize that knowledge, and we help develop the intellectual property (IP) strategy."

About SARmont
SARmont, a trusted provider of medicinal chemistry design and lead optimization services, helps accelerate the drug design process and increase the probability of success. SARmont's design team is led by Dr. John Talley, one of the world's most accomplished medicinal chemists, who is recognized for inventing Celebrex® and seven other drugs that reached the market. Acting as a virtual medicinal chemistry arm, SARmont identifies high-quality, proprietary drug candidates and helps develop IP strategy for its client companies. SARmont's unique partnership approach, which includes cost-effective relationships with Asian contract research organizations, lets clients keep the rights to all intellectual property. For more information, visit www.sarmont.com.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.